Sean Mackay Biography and Net Worth

SVP of Standard BioTools

Sean Mackay is Chief Business Officer at Standard BioTools. He has a multidisciplinary background as an executive, investor and investment banker, driving impact in the life sciences tools and therapeutics industries.

Prior to joining Standard BioTools, Sean was the co-founder and CEO of IsoPlexis (NASD: ISO), a life science tools company, where he led the company through building a team, product development, commercialization, IPO, and its eventual sale in 2023.  He also founded a debt advisory practice Lazard Freres (NYSE: LAZ), which focused on partnering with public companies for debt restructuring, capital structuring, investments, and financing in the context of acquisitions and divestitures. Sean previously served as an Operating Partner at Casdin Capital and sits on multiple boards in the life science tools and bioprocessing space.

Sean is passionate about engaging the scientific and medical community in the commercialization of precision medicine. He has co-authored 20 peer reviewed scientific publications, in Cell, Nature Medicine and Science Translational Medicine, and has several issued and pending patents related to proteomics, cell-based assays and immunotherapies.

Sean has a BS in Economics from the Wharton School at the University of Pennsylvania, and an MBA from Yale School of Management.

What is Sean Mackay's net worth?: The estimated net worth of Sean Mackay is at least $1.26 million as of May 23rd, 2025. Mr. Mackay owns 843,076 shares of Standard BioTools stock worth more than $1,256,183 as of December 16th. This net worth estimate does not reflect any other assets that Mr. Mackay may own. Learn More about Sean Mackay's net worth.
How do I contact Sean Mackay?: The corporate mailing address for Mr. Mackay and other Standard BioTools executives is 2 Tower Place Ste 2000, South San Francisco CA, 94080. Standard BioTools can also be reached via phone at (650) 266-6000 and via email at [email protected]. Learn More on Sean Mackay's contact information.
Has Sean Mackay been buying or selling shares of Standard BioTools?: Sean Mackay has not been actively trading shares of Standard BioTools during the last ninety days. Most recently, Sean Mackay sold 13,217 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.94, for a transaction totalling $12,423.98. Following the completion of the sale, the senior vice president now directly owns 843,076 shares of the company's stock, valued at $792,491.44. Learn More on Sean Mackay's trading history.
Who are Standard BioTools' active insiders?: Standard BioTools' insider roster includes Michael Egholm (President & CEO), Hanjoon Kim (CFO), and Sean Mackay (SVP). Learn More on Standard BioTools' active insiders.
Are insiders buying or selling shares of Standard BioTools?: In the last twelve months, Standard BioTools insiders bought shares 24 times. They purchased a total of 17,279,179 shares worth more than $21,064,912.74. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 58,089 shares worth more than $57,450.84. The most recent insider tranaction occured on December, 4th when Director Casdin Partners Master Fund, L bought 150,000 shares worth more than $217,500.00. Insiders at Standard BioTools own 23.2% of the company. Learn More about insider trades at Standard BioTools.
Information on this page was last updated on 12/4/2025.

Sean Mackay Insider Trading History at Standard BioTools

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/23/2025	Sell	13,217	$0.94	$12,423.98	843,076
5/22/2025	Sell	12,536	$1.00	$12,536.00	856,293
5/21/2025	Sell	12,838	$1.03	$13,223.14	868,829

Sean Mackay Buying and Selling Activity at Standard BioTools

Standard BioTools Company Overview

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.49

$1.48

$1.54

50 Day Range

MA: $1.32

$1.12

$1.51

2 Week Range

Now: $1.49

$0.92

$2.25

Volume

1,480,563 shs

Average Volume

1,683,025 shs

Market Capitalization

$573.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23